0	0	1999-09-22	CD	O	O	B-Num
0	1	13	CD	O	O	B-Num
0	2	:	:	O	O	I-Num
0	3	31	CD	O	B-NP	I-Num
0	4	GENZYME	NNP	O	I-NP	O
0	5	'S	VBZ	O	B-VP	O
0	6	GOLDEN	NNP	O	O	O
0	7	GOATS	NNP	O	O	B-Animal

1	0	CHARLTON	NNP	O	B-NP	O
1	1	COMMA	COMMA	O	O	O
1	2	Mass.	NNP	O	B-NP	O
1	3	_	NN	O	I-NP	O
1	4	Eight	CD	O	B-NP	B-Num
1	5	years	NNS	O	I-NP	B-Date
1	6	ago	IN	O	O	O
1	7	Genzyme	NNP	O	B-NP	B-OrgCorp
1	8	Corp.	NNP	O	I-NP	I-OrgCorp
1	9	set	VBD	O	B-VP	O
1	10	about	IN	O	B-PP	O
1	11	building	VBG	O	B-VP	O
1	12	a	DT	O	B-NP	O
1	13	$110	NN	O	I-NP	B-Money
1	14	million	CD	O	I-NP	B-Num
1	15	cathedral-like	JJ	O	I-NP	O
1	16	bio-manufacturing	NN	O	I-NP	O
1	17	plant	NN	O	I-NP	B-Plant
1	18	in	IN	O	B-PP	O
1	19	Boston	NNP	O	B-NP	B-LocCit
1	20	to	TO	O	B-VP	O
1	21	make	VB	O	I-VP	O
1	22	a	DT	O	B-NP	O
1	23	single	JJ	O	I-NP	O
1	24	drug	NN	O	I-NP	B-Medical
1	25	that	WDT	O	B-NP	O
1	26	sells	VBZ	O	B-VP	O
1	27	for	IN	O	B-PP	O
1	28	$170COMMA000	NN	O	B-NP	B-Money
1	29	annually	RB	O	O	O
1	30	.	.	O	O	O

2	0	If	IN	O	O	O
2	1	Genzyme	NNP	O	B-NP	B-OrgCorp
2	2	's	POS	O	B-NP	O
2	3	executives	NNS	O	I-NP	B-ProfTitle
2	4	could	MD	O	B-VP	O
2	5	have	VB	O	I-VP	O
2	6	done	VBN	O	I-VP	O
2	7	it	PRP	O	B-NP	O
2	8	all	DT	O	B-NP	O
2	9	over	IN	O	O	O
2	10	again	RB	O	O	O
2	11	COMMA	COMMA	O	O	O
2	12	they	PRP	O	B-NP	O
2	13	'd	MD	O	B-VP	O
2	14	have	VB	O	I-VP	O
2	15	skipped	VBD	O	I-VP	O
2	16	the	DT	O	B-NP	O
2	17	sophisticated	JJ	O	I-NP	O
2	18	bio-reactors	NN	O	I-NP	O
2	19	COMMA	COMMA	O	O	O
2	20	lengthy	JJ	O	B-NP	O
2	21	stainless	JJ	O	I-NP	O
2	22	steel	NN	O	I-NP	O
2	23	plumbing	NN	O	I-NP	O
2	24	COMMA	COMMA	O	O	O
2	25	and	CC	O	O	O
2	26	high-priced	JJ	O	B-NP	O
2	27	architecture	NN	O	I-NP	O
2	28	COMMA	COMMA	O	O	O
2	29	and	CC	O	O	O
2	30	bought	VBD	O	B-VP	O
2	31	a	DT	O	B-NP	O
2	32	farm	NN	O	I-NP	O
2	33	.	.	O	O	O

3	0	There	EX	O	B-NP	O
3	1	they	PRP	O	B-NP	O
3	2	might	MD	O	B-VP	O
3	3	have	VB	O	I-VP	O
3	4	produced	VBN	O	I-VP	O
3	5	the	DT	O	B-NP	O
3	6	same	JJ	O	I-NP	O
3	7	drug	NN	O	I-NP	B-Medical
3	8	COMMA	COMMA	O	O	O
3	9	called	VBD	O	B-VP	O
3	10	Cerezyme	NNP	O	B-NP	B-Peop
3	11	COMMA	COMMA	O	O	O
3	12	at	IN	O	B-PP	O
3	13	a	DT	O	B-NP	O
3	14	fraction	NN	O	I-NP	B-Medical
3	15	of	IN	O	B-PP	O
3	16	the	DT	O	B-NP	O
3	17	former	JJ	O	I-NP	O
3	18	cost	NN	O	I-NP	O
3	19	COMMA	COMMA	O	O	O
3	20	using	VBG	O	B-VP	O
3	21	some	DT	O	B-NP	O
3	22	imported	VBN	O	I-NP	O
3	23	New	NNP	O	I-NP	B-LocCoun
3	24	Zealand	NNP	O	I-NP	I-LocCoun
3	25	goats	NNS	O	I-NP	B-Animal
3	26	housed	VBD	O	B-VP	O
3	27	in	IN	O	B-PP	O
3	28	spotless	JJ	O	B-NP	O
3	29	barns	NNS	O	I-NP	O
3	30	and	CC	O	O	O
3	31	tended	VBD	O	B-VP	O
3	32	by	IN	O	B-PP	O
3	33	a	DT	O	B-NP	O
3	34	70-person	JJ	O	I-NP	B-Num
3	35	staff	NN	O	I-NP	O
3	36	COMMA	COMMA	O	O	O
3	37	including	VBG	O	B-PP	O
3	38	veterinarians	NNS	O	B-NP	B-ProfTitle
3	39	with	IN	O	B-PP	O
3	40	a	DT	O	B-NP	O
3	41	molecular	JJ	O	I-NP	B-Jour
3	42	biology	NN	O	I-NP	I-Jour
3	43	lab	NN	O	I-NP	O
3	44	and	CC	O	O	O
3	45	a	DT	O	B-NP	O
3	46	hospital-style	JJ	O	I-NP	O
3	47	operating	VBG	O	I-NP	O
3	48	room	NN	O	I-NP	O
3	49	at	IN	O	B-PP	O
3	50	their	PP$	O	B-NP	O
3	51	disposal	NN	O	I-NP	O
3	52	.	.	O	O	O

4	0	Indeed	RB	O	O	O
4	1	COMMA	COMMA	O	O	O
4	2	Genzyme	NNP	O	B-NP	B-Peop
4	3	did	VBD	O	B-VP	O
4	4	just	RB	O	B-NP	O
4	5	that	IN	O	I-NP	O
4	6	.	.	O	O	O

5	0	Here	RB	O	O	O
5	1	COMMA	COMMA	O	O	O
5	2	on	IN	O	B-PP	O
5	3	184	CD	O	B-NP	B-Num
5	4	verdant	JJ	O	I-NP	O
5	5	acres	NNS	O	I-NP	B-NumUnit
5	6	COMMA	COMMA	O	O	O
5	7	a	DT	O	B-NP	O
5	8	Genzyme	NNP	O	I-NP	B-OrgCorp
5	9	subsidiary	NN	O	I-NP	O
5	10	COMMA	COMMA	O	O	O
5	11	Genzyme	NNP	O	B-NP	B-OrgCorp
5	12	Transgenics	NNP	O	I-NP	I-OrgCorp
5	13	Corp.	NNP	O	I-NP	I-OrgCorp
5	14	COMMA	COMMA	O	O	O
5	15	maintains	VBZ	O	B-VP	O
5	16	a	DT	O	B-NP	O
5	17	herd	NN	O	I-NP	O
5	18	of	IN	O	B-PP	O
5	19	1COMMA600	CD	O	B-NP	B-Num
5	20	goats	NNS	O	I-NP	B-Animal
5	21	whose	WP$	O	B-NP	O
5	22	lactating	JJ	O	I-NP	O
5	23	females	NNS	O	I-NP	O
5	24	are	VBP	O	B-VP	O
5	25	producing	VBG	O	I-VP	O
5	26	in	IN	O	B-PP	O
5	27	their	PP$	O	B-NP	O
5	28	milk	NN	O	I-NP	B-Food
5	29	nearly	RB	O	B-NP	O
5	30	a	DT	O	I-NP	O
5	31	dozen	NN	O	I-NP	O
5	32	other	JJ	O	I-NP	O
5	33	proposed	VBN	O	I-NP	O
5	34	drugs	NNS	O	I-NP	O
5	35	_	NN	O	I-NP	O
5	36	developmental	JJ	O	I-NP	O
5	37	therapies	NNS	O	I-NP	O
5	38	that	IN	O	B-NP	O
5	39	hold	VBP	O	B-VP	O
5	40	promise	NN	O	B-NP	O
5	41	for	IN	O	B-PP	O
5	42	treating	VBG	O	B-VP	O
5	43	diseases	NNS	O	B-NP	O
5	44	including	VBG	O	B-PP	O
5	45	arthritis	NN	O	B-NP	B-Medical
5	46	COMMA	COMMA	O	O	O
5	47	malaria	NN	O	B-NP	O
5	48	COMMA	COMMA	O	I-NP	O
5	49	diabetes	NN	O	I-NP	B-Medical
5	50	COMMA	COMMA	O	O	O
5	51	AIDS	NNP	O	B-NP	O
5	52	COMMA	COMMA	O	O	O
5	53	and	CC	O	O	O
5	54	psoriasis	NN	O	B-NP	B-Medical
5	55	.	.	O	O	O

6	0	Perhaps	RB	O	O	O
6	1	the	DT	O	B-NP	O
6	2	only	JJ	O	I-NP	O
6	3	reason	NN	O	I-NP	O
6	4	why	WRB	O	O	O
6	5	Cerezyme	NNP	O	B-NP	O
6	6	COMMA	COMMA	O	O	O
6	7	which	WDT	O	B-NP	O
6	8	is	VBZ	O	B-VP	O
6	9	used	VBN	O	I-VP	O
6	10	to	TO	O	B-VP	O
6	11	treat	VB	O	I-VP	O
6	12	a	DT	O	B-NP	O
6	13	rare	JJ	O	I-NP	O
6	14	spleen	NN	O	I-NP	O
6	15	disorder	NN	O	I-NP	B-Medical
6	16	COMMA	COMMA	O	O	O
6	17	is	VBZ	O	B-VP	O
6	18	not	RB	O	I-VP	O
6	19	being	VBG	O	I-VP	O
6	20	produced	VBN	O	I-VP	O
6	21	here	RB	O	O	O
6	22	is	VBZ	O	B-VP	O
6	23	that	IN	O	O	O
6	24	when	WRB	O	O	O
6	25	Genzyme	NNP	O	B-NP	B-Peop
6	26	was	VBD	O	B-VP	O
6	27	building	VBG	O	I-VP	O
6	28	its	PP$	O	B-NP	O
6	29	showcase	NN	O	I-NP	O
6	30	Boston	NNP	O	I-NP	B-LocCit
6	31	factory	NN	O	I-NP	O
6	32	it	PRP	O	B-NP	O
6	33	did	VBD	O	B-VP	O
6	34	not	RB	O	I-VP	O
6	35	fully	RB	O	I-VP	O
6	36	understand	VB	O	I-VP	O
6	37	the	DT	O	B-NP	O
6	38	scientific	JJ	O	I-NP	O
6	39	potential	NN	O	I-NP	O
6	40	of	IN	O	B-PP	O
6	41	goats	NNS	O	B-NP	B-Animal
6	42	.	.	O	O	O

7	0	``	``	O	O	O
7	1	By	IN	O	B-PP	O
7	2	the	DT	O	B-NP	O
7	3	time	NN	O	I-NP	O
7	4	we	PRP	O	B-NP	O
7	5	realized	VBD	O	B-VP	O
7	6	that	IN	O	O	O
7	7	we	PRP	O	B-NP	O
7	8	could	MD	O	B-VP	O
7	9	produce	VB	O	I-VP	O
7	10	Cerezyme	NNP	O	B-NP	O
7	11	using	VBG	O	B-VP	O
7	12	goats	NNS	O	B-NP	B-Animal
7	13	COMMA	COMMA	O	O	O
7	14	we	PRP	O	B-NP	O
7	15	were	VBD	O	B-VP	O
7	16	-LBR-	-LBR-	O	O	O
7	17	already	RB	O	O	O
7	18	-RBR-	-RBR-	O	O	O
7	19	very	RB	O	O	O
7	20	far	RB	O	O	O
7	21	along	IN	O	O	O
7	22	with	IN	O	B-PP	O
7	23	building	VBG	O	B-VP	O
7	24	the	DT	O	B-NP	O
7	25	Allston	NNP	O	I-NP	B-Loc
7	26	plant	NN	O	I-NP	B-Plant
7	27	and	CC	O	O	O
7	28	using	VBG	O	B-VP	O
7	29	more	RBR	O	B-NP	O
7	30	traditional	JJ	O	I-NP	O
7	31	bio-manufacturingCOMMA	NN	O	I-NP	O
7	32	''	''	O	O	O
7	33	said	VBD	O	B-VP	O
7	34	Suzanne	NNP	O	B-NP	B-Peop
7	35	Groet	NNP	O	I-NP	I-Peop
7	36	COMMA	COMMA	O	O	O
7	37	vice	NN	O	B-NP	B-ProfTitle
7	38	president	NN	O	I-NP	I-ProfTitle
7	39	of	IN	O	B-PP	O
7	40	business	NN	O	B-NP	O
7	41	development	NN	O	I-NP	O
7	42	for	IN	O	B-PP	O
7	43	Framingham-based	NNP	O	B-NP	O
7	44	Genzyme	NNP	O	I-NP	B-OrgCorp
7	45	Transgenics	NNP	O	I-NP	I-OrgCorp
7	46	COMMA	COMMA	O	O	O
7	47	which	WDT	O	B-NP	O
7	48	runs	VBZ	O	B-VP	O
7	49	the	DT	O	B-NP	O
7	50	Charlton	NNP	O	I-NP	B-OrgTeam
7	51	farm	NN	O	I-NP	O
7	52	.	.	O	O	O

8	0	Today	NN	O	B-NP	B-Date
8	1	the	DT	O	B-NP	O
8	2	farm	NN	O	I-NP	O
8	3	is	VBZ	O	B-VP	O
8	4	a	DT	O	B-NP	O
8	5	busy	JJ	O	I-NP	O
8	6	place	NN	O	I-NP	O
8	7	COMMA	COMMA	O	O	O
8	8	nearly	RB	O	B-NP	O
8	9	five	CD	O	I-NP	B-Num
8	10	years	NNS	O	I-NP	B-Date
8	11	old	JJ	O	O	O
8	12	and	CC	O	O	O
8	13	with	IN	O	B-PP	O
8	14	capacity	NN	O	B-NP	O
8	15	for	IN	O	B-PP	O
8	16	up	IN	O	B-NP	O
8	17	to	TO	O	I-NP	O
8	18	2COMMA000	CD	O	I-NP	B-Num
8	19	goats	NNS	O	I-NP	B-Animal
8	20	.	.	O	O	O

9	0	It	PRP	O	B-NP	O
9	1	focuses	VBZ	O	B-VP	O
9	2	on	IN	O	B-PP	O
9	3	producing	VBG	O	B-VP	O
9	4	proposed	VBN	O	B-NP	O
9	5	drugs	NNS	O	I-NP	O
9	6	for	IN	O	B-PP	O
9	7	such	JJ	O	B-NP	O
9	8	major	JJ	O	I-NP	O
9	9	pharmaceutical	JJ	O	I-NP	B-Medical
9	10	makers	NNS	O	I-NP	O
9	11	as	IN	O	B-PP	O
9	12	Eli	NNP	O	B-NP	B-OrgCorp
9	13	Lilly	NNP	O	I-NP	I-OrgCorp
9	14	&	CC	O	I-NP	I-OrgCorp
9	15	AMP	NNP	O	I-NP	B-OrgCorp
9	16	;	:	O	O	O
9	17	Co.	NNP	O	B-NP	O
9	18	COMMA	COMMA	O	O	O
9	19	Bristol	NNP	O	B-NP	B-Peop
9	20	Myers-Squibb	NNP	O	I-NP	I-Peop
9	21	COMMA	COMMA	O	O	O
9	22	Centocor	NNP	O	B-NP	B-OrgCorp
9	23	Corp.	NNP	O	I-NP	I-OrgCorp
9	24	COMMA	COMMA	O	O	O
9	25	and	CC	O	O	O
9	26	BASF	NNP	O	B-NP	B-OrgCorp
9	27	Corp	NNP	O	I-NP	B-OrgCorp
9	28	.	.	O	O	O

10	0	These	DT	O	B-NP	O
10	1	companies	NNS	O	I-NP	B-OrgCorp
10	2	are	VBP	O	B-VP	O
10	3	partnering	VBG	O	I-VP	O
10	4	with	IN	O	B-PP	O
10	5	Genzyme	NNP	O	B-NP	B-OrgCorp
10	6	Transgenics	NNP	O	I-NP	B-Jour
10	7	to	TO	O	B-VP	O
10	8	test	VB	O	I-VP	O
10	9	whether	IN	O	O	O
10	10	some	DT	O	B-NP	O
10	11	existing	VBG	O	I-NP	O
10	12	and	CC	O	I-NP	O
10	13	new	JJ	O	I-NP	O
10	14	drugs	NNS	O	I-NP	O
10	15	can	MD	O	B-VP	O
10	16	be	VB	O	I-VP	O
10	17	produced	VBN	O	I-VP	O
10	18	less	JJR	O	O	O
10	19	expensively	RB	O	O	O
10	20	and	CC	O	B-PP	O
10	21	with	IN	O	B-PP	O
10	22	greater	JJR	O	B-NP	O
10	23	manufacturing	NN	O	I-NP	O
10	24	flexibility	NN	O	I-NP	O
10	25	COMMA	COMMA	O	O	O
10	26	according	VBG	O	B-PP	O
10	27	to	TO	O	B-PP	O
10	28	Dr.	NNP	O	B-NP	B-ProfTitle
10	29	Sandra	NNP	O	I-NP	B-Peop
10	30	Lehrman	NNP	O	I-NP	I-Peop
10	31	COMMA	COMMA	O	O	O
10	32	president	NN	O	B-NP	B-ProfTitle
10	33	of	IN	O	B-PP	O
10	34	Genzyme	NNP	O	B-NP	B-Loc
10	35	Transgenics	NNP	O	I-NP	I-Loc
10	36	.	.	O	O	O

11	0	``	``	O	O	O
11	1	If	IN	O	O	O
11	2	you	PRP	O	B-NP	O
11	3	look	VBP	O	B-VP	O
11	4	at	IN	O	B-PP	O
11	5	the	DT	O	B-NP	O
11	6	capital	NN	O	I-NP	O
11	7	needed	VBD	O	B-VP	O
11	8	to	TO	O	I-VP	O
11	9	make	VB	O	I-VP	O
11	10	100	CD	O	B-NP	B-NumUnit
11	11	kilograms	NNS	O	I-NP	I-NumUnit
11	12	per	IN	O	B-PP	O
11	13	year	NN	O	B-NP	O
11	14	of	IN	O	B-PP	O
11	15	a	DT	O	B-NP	O
11	16	pharmaceutical	JJ	O	I-NP	B-Medical
11	17	the	DT	O	I-NP	O
11	18	traditional	JJ	O	I-NP	O
11	19	way	NN	O	I-NP	O
11	20	with	IN	O	B-PP	O
11	21	bricks	NNS	O	B-NP	O
11	22	COMMA	COMMA	O	O	O
11	23	mortar	NN	O	B-NP	O
11	24	COMMA	COMMA	O	I-NP	O
11	25	bio-reactors	NN	O	I-NP	O
11	26	COMMA	COMMA	O	O	O
11	27	and	CC	O	O	O
11	28	stainless	JJ	O	B-NP	O
11	29	steel	NN	O	I-NP	O
11	30	COMMA	COMMA	O	O	O
11	31	initial	JJ	O	O	O
11	32	production	NN	O	O	O
11	33	will	NN	O	B-VP	O
11	34	cost	VB	O	I-VP	O
11	35	between	IN	O	B-PP	O
11	36	$20	NN	O	B-NP	B-Money
11	37	million	CD	O	I-NP	B-Num
11	38	and	CC	O	O	O
11	39	$70	NN	O	B-NP	B-Money
11	40	millionCOMMA	NN	O	I-NP	O
11	41	''	''	O	O	O
11	42	said	VBD	O	B-VP	O
11	43	Lehrman	NNP	O	B-NP	B-Peop
11	44	.	.	O	O	O

12	0	``	``	O	O	O
12	1	With	IN	O	B-PP	O
12	2	transgenic	JJ	O	B-NP	O
12	3	goats	NNS	O	I-NP	B-Animal
12	4	COMMA	COMMA	O	O	O
12	5	the	DT	O	B-NP	O
12	6	costs	NNS	O	I-NP	O
12	7	are	VBP	O	B-VP	O
12	8	between	IN	O	B-PP	O
12	9	$2	NN	O	B-NP	B-Money
12	10	million	CD	O	I-NP	B-Num
12	11	and	CC	O	O	O
12	12	$5	NN	O	B-NP	B-Money
12	13	million	CD	O	I-NP	B-Num
12	14	to	TO	O	B-VP	O
12	15	produce	VB	O	I-VP	O
12	16	the	DT	O	B-NP	O
12	17	same	JJ	O	I-NP	O
12	18	amount	NN	O	I-NP	O
12	19	with	IN	O	B-PP	O
12	20	probably	RB	O	B-NP	O
12	21	35	CD	O	I-NP	B-Num
12	22	goats	NNS	O	I-NP	B-Animal
12	23	COMMA	COMMA	O	O	O
12	24	each	DT	O	B-NP	O
12	25	producing	VBG	O	B-VP	O
12	26	5	CD	O	B-NP	B-Num
12	27	to	TO	O	I-NP	O
12	28	10	CD	O	I-NP	B-NumUnit
12	29	grams	NNS	O	I-NP	I-NumUnit
12	30	of	IN	O	B-PP	O
12	31	the	DT	O	B-NP	O
12	32	protein	NN	O	I-NP	B-Medical
12	33	per	IN	O	B-PP	O
12	34	liter	NN	O	B-NP	B-NumUnit
12	35	of	IN	O	B-PP	O
12	36	milk	NN	O	B-NP	B-Food
12	37	.	.	O	O	O

13	0	It	PRP	O	B-NP	O
13	1	's	VBZ	O	B-VP	O
13	2	a	DT	O	B-NP	O
13	3	great	JJ	O	I-NP	O
13	4	business	NN	O	I-NP	O
13	5	.	.	O	O	O
13	6	''	''	O	O	O

14	0	One	CD	O	B-NP	B-Num
14	1	of	IN	O	B-PP	O
14	2	the	DT	O	B-NP	O
14	3	drugs	NNS	O	I-NP	O
14	4	that	IN	O	O	O
14	5	the	DT	O	B-NP	O
14	6	goats	NNS	O	I-NP	B-Animal
14	7	now	RB	O	O	O
14	8	produce	VBP	O	B-VP	O
14	9	COMMA	COMMA	O	O	O
14	10	antithrombin	NN	O	B-NP	O
14	11	III	NNP	O	I-NP	O
14	12	COMMA	COMMA	O	O	O
14	13	is	VBZ	O	B-VP	O
14	14	currently	RB	O	O	O
14	15	in	IN	O	B-PP	O
14	16	pivotal	JJ	O	B-NP	O
14	17	trials	NNS	O	I-NP	O
14	18	in	IN	O	B-PP	O
14	19	small	JJ	O	B-NP	O
14	20	groups	NNS	O	I-NP	B-OrgCorp
14	21	of	IN	O	B-PP	O
14	22	patients	NNS	O	B-NP	O
14	23	with	IN	O	B-PP	O
14	24	heart	NN	O	B-NP	B-Medical
14	25	conditions	NNS	O	I-NP	O
14	26	COMMA	COMMA	O	O	O
14	27	in	IN	O	B-PP	O
14	28	Europe	NNP	O	B-NP	B-Loc
14	29	and	CC	O	O	O
14	30	the	DT	O	B-NP	O
14	31	United	NNP	O	I-NP	B-LocCoun
14	32	States	NNPS	O	I-NP	I-LocCoun
14	33	COMMA	COMMA	O	O	O
14	34	to	TO	O	B-VP	O
14	35	assess	VB	O	I-VP	O
14	36	its	PP$	O	B-NP	O
14	37	efficacy	NN	O	I-NP	O
14	38	in	IN	O	B-PP	O
14	39	regulating	VBG	O	B-VP	O
14	40	blood	NN	O	B-NP	B-Medical
14	41	clotting	NN	O	I-NP	I-Medical
14	42	.	.	O	O	O

15	0	The	DT	O	B-NP	O
15	1	company	NN	O	I-NP	B-OrgCorp
15	2	plans	VBZ	O	B-VP	O
15	3	to	TO	O	I-VP	O
15	4	seek	VB	O	I-VP	O
15	5	US	PRP	O	B-NP	B-LocCoun
15	6	Food	NNP	O	I-NP	B-Food
15	7	and	CC	O	I-NP	O
15	8	Drug	NNP	O	I-NP	B-Org
15	9	Administration	NNP	O	I-NP	I-Org
15	10	approval	NN	O	I-NP	O
15	11	for	IN	O	B-PP	O
15	12	the	DT	O	B-NP	O
15	13	drug	NN	O	I-NP	B-Medical
15	14	next	JJ	O	B-NP	O
15	15	year	NN	O	I-NP	O
15	16	COMMA	COMMA	O	O	O
15	17	which	WDT	O	B-NP	O
15	18	would	MD	O	B-VP	O
15	19	make	VB	O	I-VP	O
15	20	Genzyme	NNP	O	B-NP	B-Peop
15	21	the	DT	O	B-NP	O
15	22	first	JJ	O	I-NP	B-Num
15	23	US	PRP	O	B-NP	B-LocCoun
15	24	company	NN	O	I-NP	B-OrgCorp
15	25	to	TO	O	B-VP	O
15	26	receive	VB	O	I-VP	O
15	27	such	JJ	O	B-NP	O
15	28	clearance	NN	O	I-NP	O
15	29	for	IN	O	B-PP	O
15	30	a	DT	O	B-NP	O
15	31	human	JJ	O	I-NP	B-Animal
15	32	drug	NN	O	I-NP	B-Medical
15	33	produced	VBD	O	B-VP	O
15	34	in	IN	O	B-PP	O
15	35	an	DT	O	B-NP	O
15	36	animal	NN	O	I-NP	B-Animal
15	37	.	.	O	O	O

16	0	That	DT	O	B-NP	O
16	1	would	MD	O	B-VP	O
16	2	put	VB	O	I-VP	O
16	3	it	PRP	O	B-NP	O
16	4	ahead	RB	O	B-PP	O
16	5	of	IN	O	B-PP	O
16	6	two	CD	O	B-NP	B-Num
16	7	European	JJ	O	I-NP	B-LangRace
16	8	companies	NNS	O	I-NP	B-OrgCorp
16	9	COMMA	COMMA	O	O	O
16	10	Pharming	NNP	O	B-NP	B-Peop
16	11	Group	NNP	O	I-NP	I-Peop
16	12	of	IN	O	B-PP	O
16	13	the	DT	O	B-NP	O
16	14	Netherlands	NNP	O	I-NP	B-LocCoun
16	15	COMMA	COMMA	O	O	O
16	16	which	WDT	O	B-NP	O
16	17	is	VBZ	O	B-VP	O
16	18	working	VBG	O	I-VP	O
16	19	with	IN	O	B-PP	O
16	20	rabbits	NNS	O	B-NP	O
16	21	COMMA	COMMA	O	O	O
16	22	and	CC	O	O	O
16	23	Pharmaceutial	NNP	O	B-NP	B-Org
16	24	Proteins	NNPS	O	I-NP	I-Org
16	25	Ltd.	NNP	O	I-NP	I-Org
16	26	COMMA	COMMA	O	O	O
16	27	the	DT	O	B-NP	O
16	28	Scottish	NNP	O	I-NP	B-LangRace
16	29	company	NN	O	I-NP	B-OrgCorp
16	30	best	RB	O	B-VP	O
16	31	known	VBN	O	I-VP	O
16	32	for	IN	O	B-PP	O
16	33	its	PP$	O	B-NP	O
16	34	cloned	VBN	O	I-NP	O
16	35	sheep	NN	O	I-NP	B-Animal
16	36	Dolly	NNP	O	I-NP	B-Peop
16	37	.	.	O	O	O

17	0	``	``	O	O	O
17	1	We	PRP	O	B-NP	O
17	2	see	VBP	O	B-VP	O
17	3	cloning	NN	O	B-NP	O
17	4	as	IN	O	B-PP	O
17	5	a	DT	O	B-NP	O
17	6	research	NN	O	I-NP	O
17	7	effort	NN	O	I-NP	O
17	8	that	WDT	O	B-NP	O
17	9	could	MD	O	B-VP	O
17	10	potentially	RB	O	I-VP	O
17	11	create	VB	O	I-VP	O
17	12	efficiencies	NNS	O	B-NP	O
17	13	in	IN	O	B-PP	O
17	14	production	NN	O	B-NP	O
17	15	for	IN	O	B-PP	O
17	16	usCOMMA	NN	O	B-NP	O
17	17	''	''	O	O	O
17	18	said	VBD	O	B-VP	O
17	19	Lehrman	NNP	O	B-NP	B-Peop
17	20	.	.	O	O	O

18	0	``	``	O	O	O
18	1	Our	PP$	O	B-NP	O
18	2	focus	NN	O	I-NP	O
18	3	is	VBZ	O	B-VP	O
18	4	producing	VBG	O	I-VP	O
18	5	drugs	NNS	O	B-NP	O
18	6	for	IN	O	B-PP	O
18	7	chronic	JJ	O	B-NP	B-Medical
18	8	diseases	NNS	O	I-NP	O
18	9	COMMA	COMMA	O	O	O
18	10	like	IN	O	B-PP	O
18	11	cancer	NN	O	B-NP	B-Medical
18	12	COMMA	COMMA	O	O	O
18	13	diabetes	NN	O	B-NP	B-Medical
18	14	COMMA	COMMA	O	O	O
18	15	and	CC	O	O	O
18	16	arthritis	NN	O	B-NP	B-Medical
18	17	COMMA	COMMA	O	O	O
18	18	that	IN	O	B-NP	O
18	19	require	VBP	O	B-VP	O
18	20	large	JJ	O	B-NP	O
18	21	amounts	NNS	O	I-NP	O
18	22	of	IN	O	B-PP	O
18	23	medicine	NN	O	B-NP	B-Medical
18	24	.	.	O	O	O
18	25	''	''	O	O	O

19	0	Last	JJ	O	B-NP	O
19	1	week	NN	O	I-NP	O
19	2	COMMA	COMMA	O	O	O
19	3	Genzyme	NNP	O	B-NP	B-Peop
19	4	Transgenics	NNP	O	I-NP	I-Peop
19	5	said	VBD	O	B-VP	O
19	6	that	IN	O	O	O
19	7	even	RB	O	O	O
19	8	before	IN	O	O	O
19	9	it	PRP	O	B-NP	O
19	10	gains	VBZ	O	B-VP	O
19	11	FDA	NNP	O	B-NP	O
19	12	approval	NN	O	I-NP	O
19	13	for	IN	O	B-PP	O
19	14	ATIII	NNP	O	B-NP	B-Org
19	15	's	POS	O	B-NP	O
19	16	blood-clotting	JJ	O	I-NP	O
19	17	qualities	NNS	O	I-NP	O
19	18	COMMA	COMMA	O	O	O
19	19	it	PRP	O	B-NP	O
19	20	hopes	VBZ	O	B-VP	O
19	21	to	TO	O	I-VP	O
19	22	launch	VB	O	I-VP	O
19	23	clinical	JJ	O	B-NP	B-Medical
19	24	trials	NNS	O	I-NP	O
19	25	for	IN	O	B-PP	O
19	26	a	DT	O	B-NP	O
19	27	variant	NN	O	I-NP	O
19	28	COMMA	COMMA	O	O	O
19	29	antiangiogenic	JJ	O	O	O
19	30	antithrombin	NN	O	O	O
19	31	III	NNP	O	O	O
19	32	-LBR-	-LBR-	O	O	O
19	33	or	CC	O	O	O
19	34	aaATIII	NN	O	O	O
19	35	-RBR-	-RBR-	O	O	O
19	36	with	IN	O	B-PP	O
19	37	potential	JJ	O	B-NP	O
19	38	for	IN	O	B-PP	O
19	39	treating	VBG	O	B-VP	O
19	40	cancer	NN	O	B-NP	B-Medical
19	41	.	.	O	O	O

20	0	This	DT	O	B-NP	O
20	1	proposed	VBN	O	I-NP	O
20	2	drug	NN	O	I-NP	B-Medical
20	3	targets	VBZ	O	B-VP	O
20	4	a	DT	O	B-NP	O
20	5	cancerous	JJ	O	I-NP	O
20	6	tumor	NN	O	I-NP	O
20	7	's	POS	O	B-NP	O
20	8	blood	NN	O	I-NP	O
20	9	supply	NN	O	I-NP	O
20	10	with	IN	O	B-PP	O
20	11	the	DT	O	B-NP	O
20	12	goal	NN	O	I-NP	O
20	13	of	IN	O	B-PP	O
20	14	shrinking	VBG	O	B-VP	O
20	15	it	PRP	O	B-NP	O
20	16	and	CC	O	O	O
20	17	preventing	VBG	O	B-VP	O
20	18	its	PP$	O	B-NP	O
20	19	regrowth	NN	O	I-NP	O
20	20	.	.	O	O	O

21	0	It	PRP	O	B-NP	O
21	1	was	VBD	O	B-VP	O
21	2	developed	VBN	O	I-VP	O
21	3	at	IN	O	B-PP	O
21	4	Children	NNP	O	B-NP	B-Org
21	5	's	POS	O	B-NP	O
21	6	Hospital	NNP	O	I-NP	O
21	7	in	IN	O	B-PP	O
21	8	Boston	NNP	O	B-NP	B-LocCit
21	9	in	IN	O	B-PP	O
21	10	the	DT	O	B-NP	O
21	11	laboratory	NN	O	I-NP	O
21	12	led	VBD	O	B-VP	O
21	13	by	IN	O	B-PP	O
21	14	cancer	NN	O	B-NP	B-Medical
21	15	researcher	NN	O	I-NP	B-ProfTitle
21	16	Dr.	NNP	O	I-NP	B-ProfTitle
21	17	Judah	NNP	O	I-NP	B-Peop
21	18	Folkman	NNP	O	I-NP	I-Peop
21	19	.	.	O	O	O

22	0	And	CC	O	O	O
22	1	while	IN	O	O	O
22	2	similar	JJ	O	B-NP	O
22	3	versions	NNS	O	I-NP	O
22	4	of	IN	O	B-PP	O
22	5	the	DT	O	B-NP	O
22	6	drug	NN	O	I-NP	B-Medical
22	7	are	VBP	O	B-VP	O
22	8	being	VBG	O	I-VP	O
22	9	developed	VBD	O	I-VP	O
22	10	using	VBG	O	I-VP	O
22	11	traditional	JJ	O	B-NP	O
22	12	biotechnology	NN	O	I-NP	O
22	13	manufacturing	NN	O	I-NP	O
22	14	practices	NNS	O	I-NP	O
22	15	by	IN	O	B-PP	O
22	16	EntreMed	NNP	O	B-NP	O
22	17	Inc.	NNP	O	I-NP	B-Peop
22	18	COMMA	COMMA	O	O	O
22	19	of	IN	O	B-PP	O
22	20	Rockville	NNP	O	B-NP	B-Loc
22	21	COMMA	COMMA	O	O	O
22	22	Md.	NNP	O	O	B-LocStat
22	23	COMMA	COMMA	O	O	O
22	24	Genzyme	NNP	O	B-NP	B-OrgCorp
22	25	officials	NNS	O	I-NP	O
22	26	privately	RB	O	O	O
22	27	say	VBP	O	B-VP	O
22	28	they	PRP	O	B-NP	O
22	29	have	VBP	O	B-VP	O
22	30	a	DT	O	B-NP	O
22	31	competitive	JJ	O	I-NP	O
22	32	edge	NN	O	I-NP	O
22	33	because	IN	O	O	O
22	34	they	PRP	O	B-NP	O
22	35	can	MD	O	B-VP	O
22	36	produce	VB	O	I-VP	O
22	37	their	PP$	O	B-NP	O
22	38	version	NN	O	I-NP	O
22	39	more	RBR	O	O	O
22	40	quickly	RB	O	O	O
22	41	and	CC	O	O	O
22	42	less	JJR	O	B-NP	O
22	43	expensively	RB	O	O	O
22	44	using	VBG	O	B-VP	O
22	45	goats	NNS	O	B-NP	B-Animal
22	46	.	.	O	O	O

23	0	In	IN	O	B-PP	O
23	1	the	DT	O	B-NP	O
23	2	world	NN	O	I-NP	O
23	3	of	IN	O	B-PP	O
23	4	pharmaceutical	JJ	O	B-NP	B-Medical
23	5	factories	NNS	O	I-NP	O
23	6	COMMA	COMMA	O	O	O
23	7	Genzyme	NNP	O	B-NP	B-OrgCorp
23	8	COMMA	COMMA	O	O	O
23	9	more	JJR	O	O	O
23	10	than	IN	O	B-PP	O
23	11	any	DT	O	B-NP	O
23	12	other	JJ	O	I-NP	O
23	13	US	PRP	O	B-NP	B-LocCoun
23	14	drug	NN	O	I-NP	B-Medical
23	15	or	CC	O	I-NP	O
23	16	biotech	JJ	O	I-NP	O
23	17	company	NN	O	I-NP	B-OrgCorp
23	18	COMMA	COMMA	O	O	O
23	19	is	VBZ	O	B-VP	O
23	20	devoted	VBN	O	I-VP	O
23	21	to	TO	O	B-PP	O
23	22	creating	VBG	O	B-VP	O
23	23	a	DT	O	B-NP	O
23	24	thriving	VBG	O	I-NP	O
23	25	business	NN	O	I-NP	O
23	26	in	IN	O	B-PP	O
23	27	low-cost	JJ	O	B-NP	O
23	28	manufacturing	NN	O	I-NP	O
23	29	of	IN	O	B-PP	O
23	30	protein-based	JJ	O	B-NP	O
23	31	pharmaceuticals	NNS	O	I-NP	O
23	32	using	VBG	O	B-VP	O
23	33	dairy	NN	O	B-NP	O
23	34	animials	NNS	O	I-NP	O
23	35	.	.	O	O	O

24	0	Besides	IN	O	B-PP	O
24	1	the	DT	O	B-NP	O
24	2	goat	NN	O	I-NP	B-Animal
24	3	farm	NN	O	I-NP	O
24	4	COMMA	COMMA	O	O	O
24	5	which	WDT	O	B-NP	O
24	6	is	VBZ	O	B-VP	O
24	7	the	DT	O	B-NP	O
24	8	largest	JJS	O	I-NP	O
24	9	devoted	VBN	O	O	O
24	10	to	TO	O	B-PP	O
24	11	pharmaceutical	JJ	O	B-NP	B-Medical
24	12	production	NN	O	I-NP	O
24	13	COMMA	COMMA	O	O	O
24	14	Genzyme	NNP	O	B-NP	B-OrgCorp
24	15	is	VBZ	O	B-VP	O
24	16	also	RB	O	I-VP	O
24	17	working	VBG	O	I-VP	O
24	18	with	IN	O	B-PP	O
24	19	the	DT	O	B-NP	O
24	20	Pharming	NNP	O	I-NP	B-OrgCorp
24	21	Group	NNP	O	I-NP	I-OrgCorp
24	22	to	TO	O	B-VP	O
24	23	produce	VB	O	I-VP	O
24	24	a	DT	O	B-NP	O
24	25	drug	NN	O	I-NP	B-Medical
24	26	in	IN	O	B-PP	O
24	27	the	DT	O	B-NP	O
24	28	milk	NN	O	I-NP	B-Food
24	29	of	IN	O	B-PP	O
24	30	rabbits	NNS	O	B-NP	O
24	31	to	TO	O	B-VP	O
24	32	treat	VB	O	I-VP	O
24	33	Pompe	NNP	O	B-NP	B-Peop
24	34	's	POS	O	B-NP	O
24	35	disease	NN	O	I-NP	B-Medical
24	36	COMMA	COMMA	O	O	O
24	37	a	DT	O	B-NP	O
24	38	rare	JJ	O	I-NP	O
24	39	genetic	JJ	O	I-NP	B-Medical
24	40	disorder	NN	O	I-NP	B-Medical
24	41	that	IN	O	O	O
24	42	causes	NNS	O	B-NP	O
24	43	muscular	JJ	O	B-NP	O
24	44	degeneration	NN	O	I-NP	O
24	45	in	IN	O	B-PP	O
24	46	infants	NNS	O	B-NP	O
24	47	.	.	O	O	O

25	0	``	``	O	O	O
25	1	This	DT	O	B-NP	O
25	2	technology	NN	O	I-NP	O
25	3	is	VBZ	O	B-VP	O
25	4	gaining	VBG	O	I-VP	O
25	5	a	DT	O	B-NP	O
25	6	higher	JJR	O	I-NP	O
25	7	profile	NN	O	I-NP	O
25	8	as	IN	O	B-PP	O
25	9	a	DT	O	B-NP	O
25	10	viable	JJ	O	I-NP	O
25	11	and	CC	O	I-NP	O
25	12	efficient	JJ	O	I-NP	O
25	13	option	NN	O	I-NP	O
25	14	for	IN	O	B-PP	O
25	15	production	NN	O	B-NP	O
25	16	of	IN	O	B-PP	O
25	17	therapeutic	JJ	O	B-NP	B-Medical
25	18	proteinsCOMMA	NN	O	I-NP	O
25	19	''	''	O	O	O
25	20	Mary	NNP	O	B-NP	B-Peop
25	21	Ann	NNP	O	I-NP	I-Peop
25	22	Gray	NNP	O	I-NP	I-Peop
25	23	COMMA	COMMA	O	O	O
25	24	a	DT	O	B-NP	O
25	25	biotechnology	NN	O	I-NP	O
25	26	analyst	NN	O	I-NP	B-ProfTitle
25	27	at	IN	O	B-PP	O
25	28	Raymond	NNP	O	B-NP	B-Peop
25	29	James	NNP	O	I-NP	I-Peop
25	30	&	CC	O	O	O
25	31	AMP	NNP	O	B-NP	B-OrgCorp
25	32	;	:	O	O	O
25	33	Associates	NNPS	O	B-NP	B-Org
25	34	COMMA	COMMA	O	O	O
25	35	a	DT	O	B-NP	O
25	36	Wall	NNP	O	I-NP	O
25	37	Street	NNP	O	I-NP	O
25	38	investment	NN	O	I-NP	O
25	39	firm	NN	O	I-NP	O
25	40	COMMA	COMMA	O	O	O
25	41	said	VBD	O	B-VP	O
25	42	in	IN	O	B-PP	O
25	43	a	DT	O	B-NP	O
25	44	recent	JJ	O	I-NP	O
25	45	report	NN	O	I-NP	O
25	46	.	.	O	O	O

26	0	``	``	O	O	O
26	1	Goats	NNP	O	B-NP	B-Animal
26	2	are	VBP	O	B-VP	O
26	3	attractive	JJ	O	O	O
26	4	for	IN	O	B-PP	O
26	5	this	DT	O	B-NP	O
26	6	production	NN	O	I-NP	O
26	7	process	NN	O	I-NP	O
26	8	because	IN	O	O	O
26	9	they	PRP	O	B-NP	O
26	10	breed	VBP	O	B-VP	O
26	11	rapidly	RB	O	O	O
26	12	.	.	O	O	O
26	13	''	''	O	O	O

27	0	Genzyme	NNP	O	B-NP	B-Peop
27	1	has	VBZ	O	B-VP	O
27	2	40	CD	O	B-NP	B-Num
27	3	goats	NNS	O	I-NP	B-Animal
27	4	available	JJ	O	O	O
27	5	for	IN	O	B-PP	O
27	6	its	PP$	O	B-NP	O
27	7	antithrombin	NN	O	I-NP	O
27	8	III	NNP	O	I-NP	O
27	9	clinical	JJ	O	I-NP	B-Medical
27	10	trials	NNS	O	I-NP	O
27	11	COMMA	COMMA	O	O	O
27	12	but	CC	O	O	O
27	13	because	IN	O	O	O
27	14	the	DT	O	B-NP	O
27	15	goats	NNS	O	I-NP	B-Animal
27	16	are	VBP	O	B-VP	O
27	17	so	RB	O	O	O
27	18	productive	JJ	O	O	O
27	19	COMMA	COMMA	O	O	O
27	20	only	RB	O	B-NP	O
27	21	three	CD	O	I-NP	B-Num
27	22	will	MD	O	B-VP	O
27	23	be	VB	O	I-VP	O
27	24	needed	VBN	O	I-VP	O
27	25	to	TO	O	B-VP	O
27	26	make	VB	O	I-VP	O
27	27	enough	RB	O	B-NP	O
27	28	of	IN	O	B-PP	O
27	29	the	DT	O	B-NP	O
27	30	compound	NN	O	I-NP	O
27	31	for	IN	O	O	O
27	32	the	DT	O	B-NP	O
27	33	tests	NNS	O	I-NP	O
27	34	.	.	O	O	O

28	0	With	IN	O	O	O
28	1	goats	NNS	O	B-NP	B-Animal
28	2	instead	RB	O	B-PP	O
28	3	of	IN	O	I-PP	O
28	4	complex	JJ	O	B-NP	O
28	5	bio-reactor	NN	O	I-NP	O
28	6	equipment	NN	O	I-NP	O
28	7	COMMA	COMMA	O	O	O
28	8	said	VBD	O	B-VP	O
28	9	Gregory	NNP	O	B-NP	B-Peop
28	10	Liposky	NNP	O	I-NP	I-Peop
28	11	COMMA	COMMA	O	O	O
28	12	vice	NN	O	B-NP	B-ProfTitle
28	13	president	NN	O	I-NP	I-ProfTitle
28	14	of	IN	O	B-PP	O
28	15	operations	NNS	O	B-NP	O
28	16	at	IN	O	B-PP	O
28	17	the	DT	O	B-NP	O
28	18	Genzyme	NNP	O	I-NP	B-OrgCorp
28	19	Transgenics	NNP	O	I-NP	I-OrgCorp
28	20	farm	NN	O	I-NP	O
28	21	COMMA	COMMA	O	O	O
28	22	``	``	O	O	O
28	23	We	PRP	O	B-NP	O
28	24	can	MD	O	B-VP	O
28	25	make	VB	O	I-VP	O
28	26	large	JJ	O	B-NP	O
28	27	amounts	NNS	O	I-NP	O
28	28	of	IN	O	B-PP	O
28	29	protein-based	JJ	O	B-NP	O
28	30	drugs	NNS	O	I-NP	O
28	31	COMMA	COMMA	O	O	O
28	32	such	JJ	O	B-PP	O
28	33	as	IN	O	I-PP	O
28	34	for	IN	O	B-PP	O
28	35	malaria	NN	O	B-NP	O
28	36	and	CC	O	I-NP	O
28	37	arthritis	NN	O	I-NP	B-Medical
28	38	COMMA	COMMA	O	O	O
28	39	that	DT	O	B-NP	O
28	40	are	VBP	O	B-VP	O
28	41	just	RB	O	O	O
28	42	simply	RB	O	O	O
28	43	too	RB	O	O	O
28	44	expensive	JJ	O	O	O
28	45	to	TO	O	B-VP	O
28	46	produce	VB	O	I-VP	O
28	47	any	DT	O	B-NP	O
28	48	other	JJ	O	I-NP	O
28	49	way	NN	O	I-NP	O
28	50	.	.	O	O	O
28	51	''	''	O	O	O

29	0	The	DT	O	B-NP	O
29	1	company	NN	O	I-NP	B-OrgCorp
29	2	recently	RB	O	O	O
29	3	purchased	VBD	O	B-VP	O
29	4	an	DT	O	B-NP	O
29	5	additional	JJ	O	I-NP	O
29	6	184	CD	O	I-NP	B-NumUnit
29	7	acres	NNS	O	I-NP	I-NumUnit
29	8	adjacent	JJ	O	O	O
29	9	to	TO	O	B-PP	O
29	10	the	DT	O	B-NP	O
29	11	current	JJ	O	I-NP	O
29	12	farm	NN	O	I-NP	O
29	13	for	IN	O	B-PP	O
29	14	future	JJ	O	B-NP	O
29	15	expansion	NN	O	I-NP	O
29	16	.	.	O	O	O

30	0	Just	RB	O	O	O
30	1	outside	JJ	O	O	O
30	2	Liposky	NNP	O	B-NP	B-Peop
30	3	's	POS	O	B-NP	O
30	4	office	NN	O	I-NP	O
30	5	are	VBP	O	B-VP	O
30	6	photographs	NNS	O	B-NP	O
30	7	of	IN	O	B-PP	O
30	8	Genzyme	NNP	O	B-NP	B-OrgCorp
30	9	executives	NNS	O	I-NP	B-ProfTitle
30	10	COMMA	COMMA	O	O	O
30	11	including	VBG	O	B-PP	O
30	12	chief	NN	O	B-NP	B-ProfTitle
30	13	executive	NN	O	I-NP	B-ProfTitle
30	14	Henri	NNP	O	I-NP	B-Peop
30	15	Termeer	NNP	O	I-NP	I-Peop
30	16	COMMA	COMMA	O	O	O
30	17	that	IN	O	B-NP	O
30	18	mimic	VBP	O	B-VP	O
30	19	the	DT	O	B-NP	O
30	20	current	JJ	O	I-NP	O
30	21	American	NNP	O	I-NP	B-LangRace
30	22	Dairy	NNP	O	I-NP	O
30	23	Association	NNP	O	I-NP	B-OrgCorp
30	24	milk	NN	O	I-NP	B-Food
30	25	mustache	NN	O	I-NP	O
30	26	ads	NNS	O	I-NP	O
30	27	.	.	O	O	O

31	0	Termeer	NNP	O	B-NP	B-Peop
31	1	's	POS	O	B-NP	O
31	2	bears	VBZ	O	B-VP	O
31	3	the	DT	O	B-NP	O
31	4	tag	NN	O	I-NP	O
31	5	line	NN	O	I-NP	O
31	6	:	:	O	O	O
31	7	``	``	O	O	O
31	8	We	PRP	O	B-NP	O
31	9	put	VBD	O	B-VP	O
31	10	more	JJR	O	B-NP	O
31	11	in	IN	O	B-PP	O
31	12	the	DT	O	B-NP	O
31	13	mustache	NN	O	I-NP	O
31	14	.	.	O	O	O
31	15	''	''	O	O	O
